Post My Press Release

Free Press Release Distribution

Category: Biotechnology (Page 1 of 80)

Hospital Acquired Infections (HAI) Diagnostics Market Trends, Demand, Production, Growth Analysis And Forecast To 2022 : Grand View Research Inc.

San Francisco, 16 May 2019: The Report Hospital Acquired Infections (HAI) Diagnostics Market Size & Forecast By Infection Type (Blood Stream Infection, Surgical Site Infection, Urinary Tract Infection, Pneumonia, Gastrointestinal, Cardiovascular infections), By Test Type (Molecular Diagnostics, Blood Tests, Urinalysis), By Region (U.S., Canada, Germany, UK, China, India, Brazil, Mexico, Nigeria) And Trend Analysis From 2012 To 2022

Global Hospital Acquired Infections (HAI) Diagnostics Market is expected to reach USD 11.6 billion by 2022, according to a new report by Grand View Research, Inc.

The global hospital acquired infections diagnostics market is projected to grow at a healthy CAGR during the period of 2015 to 2022. Factors attributing to the growth of the market are increase in the number of drug-resistant pathogens such as MRSA and Cdifficile, advancing age of geriatric population, and development of technologically advanced products that offer accurate and reliable results with low turnaround time. 

Another factor contributing to industry growth is the increasing demand of HAI diagnostics from middle and low income countries, further driving demand for HAI diagnostic market. Increasing awareness among healthcare workers and proposed government initiatives are further supporting industry growth. However, decline in the prevalence rate of nosocomial infections in the developed countries is likely to hinder industry growth. 

The HAI diagnostics market is categorized on the basis of infection type and test type. On the basis of infection type, the market is segmented into Urinary Tract Infection (UTI), Blood Stream Infection (BSI), Surgical Site Infection (SSI), pneumonia, and others. As of 2015, the urinary tract infection segment was estimated to account for the largest share, whereas the pneumonia HAI diagnostics is projected to grow at the highest CAGR during the period of 2015 to 2022.The HAI diagnostics industry is further segmented into molecular tests and other in-vitro tests. Though the molecular diagnostics segment is estimated to constitute a low share, it is anticipated to witness a lucrative growth in the next few years.

Access Research Report of Hospital Acquired Infections (HAI) Diagnostics Market @ www.grandviewresearch.com/industry-analysis/hospital-acquired-infections-hai-diagnostics-market

Further key findings from the study suggest:

  • In the year 2015, North America held the largest share in the industry in terms of value. The rising awareness of HAI, application of technologically advanced products, and significant measures taken by the government to counter HAIs are some of the major factors contributing to industry growth.
  • The AsiaPacific is projected to witnessthe highest growth in the coming years, as incidence of HAIs is on rise in the region. This market is projected to grow rapidly at the highest CAGR of around 20% during the period 2015 to 2022.
  • As of 2015, the diagnostic market for UTI acquired in hospitals led the industry at a global level. On the other hand, the pneumonia segment is expected to witness the highest growth over the forecast period.
  • The industry constitutes of numerous local and global players. Some key players of this market include bioMérieux, Abbott Laboratories, Roche AG, and Siemens Healthcare among others. 

Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/biotechnology

Grand View Research has segmented the global hospital acquired infections diagnostic market on the basis of infection type, test type, and region:

Hospital Acquired Infections Diagnostic Infection Type Outlook (Revenue, USD Million, 2012 – 2022)

  • Bloodstream Infections (BSI)
  • Urinary Tract Infections (UTI)
  • Surgical Site Infections (SSI)
  • Pneumonia
  • Others

Hospital Acquired Infections Diagnostic Test Type Outlook (Revenue, USD Million, 2012 – 2022)

  • Molecular Diagnostics Tests
  • Other In-vitro Diagnostic Tests

Hospital Acquired Infections Diagnostic Regional Outlook (Revenue, USD Million, 2012 – 2022)

  • North America
  • Europe
  • AsiaPacific
  • Latin America
  • MEA

Access Press Release of Hospital Acquired Infections (HAI) Diagnostics Market @ www.grandviewresearch.com/press-release/global-hai-diagnostics-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

Craniomaxillofacial Implants Market Positioning, Revenue, Growth Factors and Forecast Till 2026

Craniomaxillofacial implants is revolutionizing the healthcare industry by providing improved treatment options for facial and cranial injuries or any craniomaxillofacial abnormalities. 3D printing technology is also enabling manufacturers to provide customized implants according to the requirement of patients, which makes the market more attractive. Road accidents are considered to be the common reason for most of the craniomaxillofacial injuries. Increased incidence of facial fractures is expected to propel the global craniomaxillofacial market. According to a study examining the epidemiology of boxing injuries in the U.S., in 2013, head and neck injuries accounted for 22.5%, leading to increase in craniomaxillofacial surgeries. In 2012, a study conducted by the Michigan State University revealed that the rate of craniomaxillofacial injuries in people not wearing helmets was 37.2%. According to the Association for Safe International Road Travel in the U.S., almost 2.35 million people are injured each year in road accidents, which, in turn, support the craniomaxillofacial implants market.
Download the PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/773
Market DynamicsCraniomaxillofacial implants offer benefits such as customization based on the requirement of patient with the help of newly advanced 3D printing technology. Furthermore, growing prevalence of facial injuries is also expected to favor the growth of craniomaxillofacial implants. Emerging techniques for facial and cranial surgical procedures with higher success rate will also promote the use of craniomaxillofacial implants throughout the forecast period. Introduction of robotic arm assisted craniomaxillofacial surgery makes the surgery safer and efficient. Advancements in bioabsorable implants for cranial fixation are expected to drive the craniomaxillofacial implants market. Modern approaches such as image-based 3D modeling using computer-assisted design (CAD) and computer-assisted manufacturing (CAM) of implants to create surgical templates that are more precise than the other craniomaxillofacial implants, which is expected to increase the market for craniomaxillofacial implants.
Market TaxonomyThis report segments the global craniomaxillofacial implants for the medical sector market, on the basis of product, raw material, application, property, and region. On the basis of product, the global craniomaxillofacial implants market is classified into bone graft substitutes, distraction systems, total TMJ replacement systems, cranial flap fixation systems, thoracic fixation systems, dural repair products and screw, plates, and contourable mesh. Raw materials for craniomaxillofacial implants include metals, ceramics, polymers, and biomaterials. The internal fixators and external fixators are segmented under application segment. On the basis of property, the global craniomaxillofacial implants market is classified into resorbable fixators and non-resorbable fixators.
Key features of the study:This report provides an in-depth analysis of global craniomaxillofacial implants in medical sector and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2016 as the base yearIt elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this marketThis study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading playersIt profiles leading players in the global craniomaxillofacial implants for medical sector market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plansKey companies covered as a part of this study include Stryker Corporation, Johnson & Johnson, Zimmer Biomet Holdings, Inc., Medtronic plc, Integra LifeSciences Holdings Corporation, OsteoMed L.P., Medartis AG, KLS Martin, Calavera Surgical Design, and Matrix Surgical USA.
Patient specific implants, 3D implants, growing demand for bioresorbable materials, and growing adoption of robot assisted surgeries have simplified the complexity of craniomaxillofacial surgeries. Whereas, advanced techniques, including computer-assisted craniofacial reconstruction, distraction osteogenesis, and endoscopic procedures, combined with refinements in surgical equipment such as resorbable plating and distractors, have improved surgical outcomes, while minimizing morbidity. The development of bone graft substitutes with the help of gene thera py and nanotechnology is also expected to drive the craniomaxillofacial implants market.
Some major players operating in the craniomaxillofacial implants market include Stryker Corporation, Johnson & Johnson, Zimmer Biomet Holdings, Inc., Medtronic plc, Integra LifeSciences Holdings Corporation, OsteoMed L.P., Medartis AG, KLS Martin, Calavera Surgical Design, and Matrix Surgicssal USA.
Click To Read More On Craniomaxillofacial Implants Market
About Coherent Market Insights:Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Hospital Pharmaceuticals Market: Competitive Dynamics & Global Outlook 2026

Hospital pharmaceutical consists of pharmaceuticals which are purchased by hospitals and used for treatment of either inpatients or outpatients. Hospital pharmaceutical drugs includes critical care and therapeutic drugs applied in infections, alimentary tract and metabolism, cardiology, urology, neurology, sensory organs, musculoskeletal system, respiratory system, dermatology, hematology and other. The primary responsibility of hospital pharmacy is procurement, storage and selling of medications. Hospital pharmaceuticals consists of medicines purchased for hospitals, healthcare centers in order to be administered to patients during hospital enabled treatment period.
The procurement of hospital pharmaceuticals for inpatients are not regulated by any legislation. Price of hospital pharmaceuticals are based on the negotiations between the hospital pharmacy and pharmaceutical company, especially in case of bulk purchases. However, hospital pharmacies are free to negotiate purchasing price with the industries officials depending on hospital needs and competition between the suppliers in market to receive hospital formulary.
Request Sample Copy of This Research: https://www.coherentmarketinsights.com/insight/request-sample/2611
For instance, Pharmac, a New Zealand government agency takes the decision about which medicines should be publically funded to help the patients get medicines at subsidized price and make choices on spending of District Health Board (DHB) on medical treatments. Pharmac with their increased horizon in vaccines, haemophilia treatments, cancer treatments and hospital medicines segment takes decisions on medicines funded in DHB hospitals and negotiates on budget management of hospital medicines. Pharmac publishes the list of subsidiarised medicine and drugs in their pharmaceutical schedule, annually. Pharmaceutical schedule list consists of formulations, doses, subsidy price of medicine and prescribing guidelines and it made accessible to health professionals and pharmacists.
Hospital Pharmaceuticals Market Drivers:High prevalence of chronic diseases is a major factor driving the hospital pharmaceuticals market. According to the World Health Organization (WHO), in 2015 around 17.7 million people died due the cause of cardiovascular disease (CVD), representing 31% of all world deaths. Over three quarters of the total CVD deaths take place in low and middle income countries, indicating in the need for better medications in such regions. According to WHO, globally 8.8 million people died due to the cause of cancer in 2015, which majorly includes lung, stomach, liver, colorectal and female breast cancer. According to data published by National Center for Complementary and Integrative Health (NCCIH), in August 2015, 25.3 million U.S. people were suffered from daily pain.
Hospital Pharmaceuticals Market Taxonomy:By Therapeutic application:

  • Cardiology
  • Oncology
  • Nephrology
  • Urology
  • Neurology
  • Pain & Infection

According to the report published by, NORC at the University of Chicago, in October 2016, 90% of hospital administrators in U.S. reported that, the increased drug prices during the period 2013 to 2015, and growth in inpatient drug spending made the moderate to severe impact on hospital pharmaceutical budget. The major findings by Federation of American Hospitals (FAH) highlighted that inpatient spending increased by 38.7% on per hospital admission, from 2013 to 2015, affecting hospitals ability to manage overall healthcare costs. The large and uncertain increase in the hospital associated drug cost could significantly impact the hospitals’ ability to manage cost within the Medicare’s fixed price based payment system.
Hospital Pharmaceuticals Market Competitive Analysis:Key players operating in the hospital pharmaceuticals market includes Bayer AG, Novartis AG, Pfizer, Inc., AstraZeneca plc, GlaxoSmithKline plc, Johnson & Johnson, F. Hoffmann-La Roche Ltd, Sanofi S.A., Merck & Co., Inc. and Eli Lilly and Company.
Click To Read More On Hospital Pharmaceuticals Market
About Coherent Market Insights:Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Solid Tumors Treatment Market Size Historical Growth Analysis To 2026

A solid tumor is an abnormal mass or lump of tissues without liquid or cysts. It is not necessary that tumor should always be cancerous. On the basis tumor nature, it can be classified as the malignant tumor (cancerous) and the benign tumor (non-cancerous). Based on the cell type, tumors can be classified as carcinomas, sarcomas, and lymphomas. The Solid tumors might occur in several places such as muscle, bone, and organs. Treatments for solid tumors include prevention of tumor and combination of surgery, chemotherapy, and radiation therapy. However, new forms of treatment are emerging in the market.
Emerging trend of Biosimilars therapy is expected to propel the growth of solid tumors treatment marketAccording to data published in International Journal of Pharma Sciences and Research (IJPSR) in 2011, there were around 9 million deaths due to cancer. In 2015, 11.4 million people are expected to die in 2030, among this prevalence of cancer maximum is due to solid tumors. Growing prevalence of solid tumors is the major driving factor for the growth of solid tumors treatment market. Additionally, some other factors fuelling the growth of solid tumors treatment market include unmet demand for cancer treatment and rising investment in the research and development of cancer drugs. However, increase in the volume of generic therapeutic products, the high cost of cancer therapy, and growing drug patent cliff are some of the restraints that might hinder the growth of solid tumors treatment market. Moreover, the emerging trend of biosimilars is contributing to the growth of solid tumors treatment market due to their low cost and their similarity to originator compound. For instance, some of the biologics available for solid tumors treatment includes Herceptin, MabThera, Avastin, and Erbitux. The advantages of this biosimilars to overcome the limitations of generic drugs in the treatments is expected to propel the growth of solid tumors treatments market.
Request For Sample Copy of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/793
Chemotherapy segment holds the maximum share in solid tumor treatment market due to its efficacy by combining with some other therapies to treat solid tumors.The global solid tumors treatment market is segmented by therapy, by application, by the end user, and by region.On the basis of therapy, solid tumors treatment market is segmented into

  • Radiotherapy
  • Chemotherapy
  • Immunotherapy
  • Hormone therapy
  • Targeted therapy

Rising incidences of solid tumor cases in North America is the factor contributing to the growth of solid tumor treatment marketRegional segmentation of Solid Tumors Treatment market by Coherent Market Insights comprises of North America, Latin America, Europe, Asia Pacific, Africa, and the Middle East. North America dominates in the solid tumors treatment market due to the presence of well-established healthcare infrastructure, and rise in the number of solid tumor cases.
Advanced drug therapy is expected to help the industry players to sustain in the solid tumors treatment marketKey industry players operating solid tumors treatment market include Abbott Laboratories Inc., Biogen Idec Incorporated, AstraZeneca Plc., Johnson & Johnson Company, Amgen Inc., Bristol Myers Squibb Company, GlaxoSmithKline Plc., Sanofi, and Baxter International Incorporated. Advancements in the cancer therapy such as nanomedicines used for the treatment of cancer might help the industry players to provide effective patient care in the solid tumors treatment. Whereas, stringent regulatory policies for drug manufacturing may restrain the growth of the market. For instance, by regulations provided by the Indian government in late 2012, there are cap prices of 348 drugs on Essential Drug List (EDL), and drug manufacturers need to keep the cost of their drugs below the ceiling price.
Click to read more on Solid Tumors Treatment Market
About Coherent Market Insights:Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Monoclonal Antibodies (mAbs) Market Future Growth ,Industry Size ,Share ,Revenue And Forecast For 2024 : Grand View Research Inc.

San Francisco, 22 May 2019: The Report Monoclonal Antibodies (mAbs) Market Analysis By Source (Chimeric, Murine, Humanized, Human), By Type of Production, By Indication (Cancer, Autoimmune, Inflammatory, Infectious, Microbial, Viral Diseases), By End-use (Hospitals, Research, Academic Institutes, Clinics, Diagnostic Laboratories) And Segment Forecasts, 2018 – 2024

The global Monoclonal Antibodies (mAbs) Market was valued at USD 85.4 billion in 2015 and is expected to reach a value of USD 138.6 billion by 2024. Increasing R&D pertaining to the development of therapeutic mAbs coupled with supportive government initiatives is expected to drive the monoclonal antibodies market growth over the forecast period.

Increasing demand for personalized medicine is a vital factor responsible for the increasing development of therapeutic antibodies to provide targeted therapies as every individual responds in a different manner to a particular treatment. Moreover, related benefits of using mAbs for therapeutic purposes, including fewer adverse effects, homogeneity, specificity, and large-scale production, are contributing toward significant market growth.

In addition, the government initiatives to enable cost-effective production of mAbs is anticipated to propel the emergence of this sector over the forecast period. For instance, the biomanufacturing initiative byNational Institute of Standards and Technology in the U.S. provides scientifically sound regulatory guidelines to ensure effective and safe manufacturing of protein therapeutics and to support biopharmaceutical manufacturers in offering low-cost and high-quality protein drugs across the globe.

Access Research Report of Monoclonal Antibodies (mAbs) Market @ www.grandviewresearch.com/industry-analysis/monoclonal-antibodies-market

Further Key Findings from the Study Suggest:

  • Human-based mAbs segment is predicted to grow at a lucrative CAGR in the coming years due to their associated benefits and numerous R&D activities conducted for further development of human mAbs. Large number of mAbs of human origin are in phase III clinical trial for cancer treatment
  • In vitro production of mAbs is anticipated to show the fastest growth owing to its wide-scale adoption by biologics manufacturers due to its greater efficiency in cost and time
  • The research institute segment is anticipated to exhibit profitable growth due to increasing R&D efforts in the biotech industry as monoclonal antibodies have emerged as a major class of therapeutics for several human diseases, particularly immunological infectious diseases and cancer
  • The Asia pacific region has significant growth potential due to rising government initiatives in this region supporting the use of mAbs for research and treatment purposes coupled with the surge in sponsored R&D projects for the development of cost-effective therapeutic mAbs.
  • For instance, government-led fund providers, such as National Natural Science Foundation and National Basic Research Program of China, offer financial support to enterprises and universities to conduct mAb research and development.
  • The key players serving the monoclonal antibodies market arePfizer, Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc, Amgen, Inc., Abbott Laboratories, AstraZeneca, Eli Lilly and Company, Mylan N.V., Daiichi Sankyo Company, Ltd., Bayer AG, Bristol Myers Squibb Co.,Johnson & Johnson Services, Inc., Biogen Inc., Thermo Fisher Scientific, Inc., Sanofi Genzyme, F. Hoffmann-La Roche Ltd., and Novo Nordisk A/S.
  • The introduction of advanced methods for mAb production further encourages the pharmaceutical companies to build their own product pipeline. According to a study published by NCBI at the end of 2013, approximately 816 companies were involved in therapeutic protein research. 

Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/biotechnology

Grand View Research has segmented the monoclonal antibodies market by source type, production, indication, end-use, and region:

Global Monoclonal Antibodies Source Type Outlook (Revenue, USD Billion, 2013 – 2024)

  • Murine
  • Chimeric
  • Humanized
  • Human 

Global Monoclonal Antibodies Production Type Outlook (Revenue, USD Billion, 2013 – 2024)

  • In Vivo
  • In Vitro

Global Monoclonal Antibodies Indication Outlook (Revenue, USD Billion, 2013 – 2024)

  • Cancer
  • Autoimmune Diseases
  • Inflammatory Diseases
  • Infectious Diseases
  • Microbial Diseases
  • Others

Global Monoclonal Antibodies End-use Outlook (Revenue, USD Billion, 2013 – 2024)

  • Hospitals
  • Research Institutes
  • Others

Monoclonal antibodies Market Regional Outlook (Market Revenue in USD Billion, 2013 – 2024)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Access Press Release of Monoclonal Antibodies (mAbs) Market @ www.grandviewresearch.com/press-release/global-monoclonal-antibodies-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

Scaffold Technology Market Trends, Demand, Production, Analysis and Forecast to 2024 : Grand View Research Inc.

San Francisco, 23 May 2019: The Report Scaffold Technology Market Size & Forecast, By Product (Hydrogels, Micro-Patterned Surface Microplates, Polymeric & Nanofiber Scaffold), By Application, By End-Use And Trend Analysis From 2018 To 2024

The global Scaffold Technology Market is anticipated to reach USD 1.5 billion by 2024, according to a new report by Grand View Research, Inc.Evolution of scaffold technology, which facilitates the transplantation process, has created opportunities to address tissue engineering-associated challenges such as vascularization. Also, scaffolds are used in the treatment of damaged and diseased organs or tissues to provide support to implants that are surgically inserted into the patient’s body. This is expected to further support the emergence of this vertical. 

Rise in the aging population and the number of organ defunctionalization cases coupled with the demand for effective treatments are some of the factors promoting the adoption of scaffold technology.

Access Research Report of Scaffold Technology Market @ www.grandviewresearch.com/industry-analysis/scaffold-technology-market

Further Key Findings from the Study Suggest:

  • In 2015, hydrogels-based scaffolds dominated the market with a share of over 41% with respect to revenue generation owing to their higher availability as well as continual progress in their development. Moreover, their promising use as cartilage tissue engineering scaffolds, which enable simultaneous cell growth and drug delivery, is fueling their adoption.
  • Even though nanofiber-based scaffolds are estimated to exhibit the lowest market penetration in the current scenario, this segment is expected to witness the fastest growth rate in the coming years due to their ability to mimic the nanoscale properties and structural characteristics of native extracellular matrix; this factor is expected to increase their incorporation in regenerative medicine and other clinical applications.
  • Biotechnology and pharmaceutical organizations held the largest share in 2015 and are expected to witness considerable growth over the forecast period due to the demand for robust tools in metabolic and toxicology profiling of drug moieties during the process of drug development. Also, several biotechnological companies have begun investing in the development of novel products targeting this vertical, which is expected to boost revenue generation through these entities.
  • In 2014, North America emerged as one of the largest markets. This is attributable to the developed healthcare infrastructure and presence of large number of key participants operating in this region. Asia pacific is expected to be one of the fastest growing regional segments owing to the rapidly improving infrastructure and favorable government initiatives pertaining to research and development in the pharmaceutical industry.
  • Some of the key players operating the market space include Merck KGaA (Sigma-Aldrich Co. LLC);Thermo Fisher Scientific, Inc.; 3D Biotek LLC; Molecular Matrix, Inc; ReproCELL Europe Ltd (Reinnervate); Xanofi; Pelo Biotech GmbH; Corning, Inc; Becton, Dickinson and Company; 3D Biomatrix; Avacta Life Sciences Limited; Nanofiber Solutions; NuVasive, Inc; Vericel Corporation; Molecular Partners; Acelity (LifeCell Corporation); and Medtronic (Covidien plc).
  • These players are undertaking different market strategies to maintain their dominance in the market. These strategic endeavors include new product development, acquisitions and mergers, partnerships, and global expansion efforts.
  • Scaffold technology is considered as the leading candidate employed to perform 3D-culture assays including high throughput screening, cell to matrix interactions, cell to cell interactions, cell migration assays, and transfections, which collectively accounted for the largest segment share in 2015 and is anticipated to witness lucrative growth in the coming years. The significant share is attributed to the increasing use of scaffold technology to study cellular behavior and understand the underlying mechanism of diseases. 

Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/biotechnology

Grand View Research has segmented the scaffold technology market on the basis of types, application, end use, and region: 

Global Outlook, by Type (Revenue, USD Million, 2013 – 2024)

  • Hydrogels
  • Polymeric Scaffolds
  • Micro-patterned Surface Microplates
  • Nanofiber-based Scaffolds

Global Outlook, by Application (Revenue, USD Million, 2013 – 2024)

  • Cancer
  • Tissue Engineering & Clinical Application
  • Drug development
  • Stem cell research
  • Others

Global Outlook, by End Use (Revenue, USD Million, 2013 – 2024)

  • Biotechnology and Pharmaceutical Organizations
  • Research Laboratories and Institutes
  • Hospitals and Diagnostic Centers
  • Others

Regional Outlook (Revenue, USD Million, 2013 – 2024)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • MEA

Access Press Release of Scaffold Technology Market @ www.grandviewresearch.com/press-release/global-scaffold-technology-market-analysis

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

Molecular Biology Enzymes And Kits & Reagents Market Anticipated To Boost The Industry Growth To Reach USD 26.7 Billion By 2025 : Grand View Research Inc.

San Francisco, 23 May 2019: The Report Molecular Biology Enzymes And Kits & Reagents Market Analysis By Product (Kits and Reagents, Enzymes), By Application (PCR, Sequencing, Cloning, Epigenetics), By End User, And Segment Forecasts, 2018 – 2025

The global Molecular Biology Enzymes And Kits & Reagents Market is expected to reach USD 26.7 billion by 2025, according to a new report by Grand View Research, Inc. Expanding pharmaceutical and biotechnology industry in emerging nations is expected to offer significant growth opportunities to the molecular biology enzymes, kits, and reagents market. Furthermore, the increasing adoption of personalized medicine is expected to provide lucrative opportunities to the market.

Technological advancements aimed at development of advanced products and increasing R&D investments by leading manufacturers are some of the key factors contributing to increasing demand for these enzymes, kits, and reagents. In addition, increasing adoption of molecular diagnostics is expected to serve this industry as a potential growth driver.

Molecular biology enzymes, kits, and reagents are majorly used in genomics-related application areas. Increased funding for research in the field of genomics and sequencing are expected to augment growth during the forecast period. Furthermore, these products are used in the drug discovery and development stages in pharmaceutical and biopharmaceutical companies.

Pharmaceutical and biotechnology companies contribute to the largest share of the end users of molecular biology enzymes, kits, and reagents. This dominant share can be attributed to increasing investments in R&D, expanding biopharmaceutical & biotechnology industry in the Asia Pacific region, and government initiatives in various countries to develop the biotechnology & pharmaceutical industry.

Access Research Report of Molecular Biology Enzymes And Kits & Reagents Market @ www.grandviewresearch.com/industry-analysis/molecular-biology-enzymes-kits-reagents-market

Further Key Findings From the Study Suggest:

  • Kits and reagents held the dominant share of market, by product, as of 2016 owing to their low costs and incessant product launches
  • Rising number of research activities in molecular biology application areas amongst the end users is one of the key contributing factors responsible for the dominance of this product
  • The Polymerase Chain Reaction (PCR) segment is expected to witness lucrative growth in the near future owing to the benefits associated with its use in molecular diagnostics
  • PCR is used in detection and identification of genetic disorders. Rising geriatric population across the globe is also expected to drive this market owing to the use of PCR in detecting and diagnosing geriatric disorders.
  • Rising demand for personalized medicine fosters the demand for sequencing, which further increases the demand for these enzymes, kits, and reagents
  • Pharmaceutical and biotechnology companies held a dominant share, by end user in 2016
  • Rising investments in R&D, expanding pharmaceutical & biotechnology industry, and increasing venture capital investments are some of the major factors contributing to the growth of this segment.

Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/biotechnology

Grand View Research has segmented the molecular biology enzymes and kits & reagents market on the basis of the product, application, end user, and region:

Molecular Biology Enzymes, Kits, and Reagents Product Outlook (Revenue, USD Million, 2014 – 2025)

  • Kits and Reagents
  • Enzymes

Molecular Biology Enzymes, Kits, and Reagents Application Outlook (Revenue, USD Million, 2014 – 2025)

  • PCR
  • Sequencing
  • Cloning
  • Epigenetics
  • Restriction Digestion
  • Synthetic Biology
  • Other Applications

Molecular Biology Enzymes, Kits, and Reagents Application Outlook (Revenue, USD Million, 2014 – 2025)

  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Hospitals and Diagnostic Centers
  • Other End Users

Molecular Biology Enzymes, Kits, and Reagents Regional Outlook (Revenue, USD Million, 2014 – 2025)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • MEA

Access Press Release of Molecular Biology Enzymes And Kits & Reagents Market @ www.grandviewresearch.com/press-release/global-molecular-biology-enzymes-kits-reagents-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

HbA1c Testing Devices Market Global Analysis, Trends, And Forecast 2018– 2026

HbA1c test is used to screen and diagnose for diabetes and prediabetes in patients. Hemoglobin molecule from the blood cell sticks to the glucose that gives rise to glycosylated hemoglobin molecule termed as hemoglobin A1C (HbA1C). Patients with high glucose level have more HbA1C present in blood. Average blood glucose level of a person can be diagnosed by measuring this glycosylated hemoglobin molecule. It is important for diabetic patient to know the glucose level, as there might be risk of diabetes related complications. HbA1c test is considered more effective than checking the blood glucose level. Blood glucose level gives the presence of glucose at a single point time whereas, the HbA1c test gives blood glucose level status for 2-3 months.

Increase in healthcare expenditure over diabetes management is owing to the growth of HbA1c testing devices market

Growing diabetes patient population globally is one of the important factor driving the growth HbA1c testing devices market. According to World Health Organization (WHO), the number of patients with diabetes has increased from 108 million in 1980 to 422 million in 2014. Around 5 million deaths were reported in 2015 due to diabetes and 2.2 million deaths were attributed to high blood glucose level. The data given by International Diabetes Federation showed the expenditure of 673 billion USD on diabetes in 2015. Additionally, rise prescription by physicians for HbA1c test is contributing to the growth of HbA1c testing devices market.

Request For Sample Copy of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/945

Wide use of bench top devices in diagnostic laboratories owing to domination of device segment

The global HbA1c testing devices market is segmented by device- type, by technology, by end users, and by region

On the basis of device- type, the HbA1c testing devices market is segmented into

Rising diabetic population is attributed to the growth of HbA1c testing devices market in Asia Pacific

Regional segmentation of HbA1c testing devices market by Coherent Market Insights comprises of North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. The increase in number of patient population in North America is fuelling the growth of HbA1c testing devices market. Furthermore, the factors like established healthcare infrastructure and adoption to the technologically advanced medical devices, are helping North America to dominate in the HbA1c testing devices market. According to recent data given by International Diabetes Federation, there are around 109 million people in China and 69 million people in India with diabetes. The large number of diabetic population, unmet health needs, and development in healthcare sector are fuelling the growth of HbA1c testing devices market in Asia Pacific.

Product development is helping the organizations in HbA1c testing devices market to hold the top position

Key industry players operating the global HbA1c market includes Abbott Laboratories, Transasia Biomedicals limited, Alere Incorporated, Arkray Incorporated, Danaher Co., Bio-Rad Laboratories, Siemens Healthcare, F.Hoffmann-La Roche Limited, and Trinity Biotech Plc. The industry players are likely to get involved in product development for higher accuracy, reliable results, and quicker turnaround time for the analyzers. The factors like product development and approval of devices for diagnosis of diabetes are helping the organizations to hold the maximum share in the HbA1c testing devices market.

Click to read more on HbA1c Testing Devices Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Page 1 of 80

Powered by WordPress & Theme by Anders Norén